Market revenue in 2023 | USD 14.4 million |
Market revenue in 2030 | USD 19.3 million |
Growth rate | 4.3% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 45.83% in 2023. Horizon Databook has segmented the Saudi Arabia neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia is the most lucrative region in the Middle East for neurology clinical trials market. The country has the largest number of hospitals and primary health centers in the region. Major upcoming projects for establishing hospitals, such as King Khalid Medical City, King Faisal Medical City, and King Abdullah Medical City, are expected to promote research, thus boosting the market in the country.
This expansion is expected to create opportunities for market players in Saudi Arabia. The King Abdullah International Medical Research Center (KAIMRC) is well-positioned to lead a national initiative to strengthen & organize clinical trial setup and make it more appealing to international industry with the help of various local partners & government support.
It is collaborating with the Saudi Food and Drug Authority (SFDA) to align legislation with rapid rate of clinical studies and develop ethical guidelines. Such initiatives are expected to fuel the growth of Saudi Arabia neurology clinical trials market.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account